SGHT Sight Sciences |
$3.49
0.0% |
-16.7%
 |
OMNI Surgical System
Pseudophakic Eyes with Open-Angle Glaucoma
|
|
9/17/2025 - Published Results
Sight Sciences, Inc. announced the results as published in the European Journal of Ophthalmology of …
Full Summary
|
NRIX Nurix Therapeutics |
$8.66
+2.6% |
-15.1%
 |
GS-6791/NX-0479
Novel IRAK4 Degrader for Inflammatory Conditions
|
|
9/17/2025 - Data Presentation
Nurix Therapeutics, Inc. announced the presentation of preclinical data from GS-6791/NX-0479, a no…
Full Summary
|
AZN AstraZeneca |
$77.62
+0.1% |
-1.9%
 |
TULIP-SC
in patients with systemic lupus erythematosus based on an interim analysis
|
|
9/17/2025 - Positive Results
Astrazenca announced Positive high-level results from a pre-specified interim analysis of the Phase …
Full Summary
|
TNXP Tonix Pharmaceuticals |
$28.01
+3.3% |
-30.1%
 |
TNX-4800
Lyme Disease
|
|
9/17/2025 - Provided Update
Tonix Pharmaceuticals announced the in-licensing of worldwide rights to TNX-4800 (formerly known as…
Full Summary
|
REGN Regeneron Pharmaceuticals |
$583.69
+1.5% |
+1.7%
 |
garetosma
Fibrodysplasia Ossificans Progressiva (FOP)
|
Phase 3
|
9/17/2025 - Endpoint Met
Regeneron Pharmaceuticals, Inc announced the primary endpoint was met in the Phase 3 OPTIMA trial i…
Full Summary
|
LLY Eli Lilly and Company |
$763.36
-0.2% |
+9.2%
 |
orforglipron
Orforglipron for the treatment of obesity and overweight
|
Phase 3
|
9/17/2025 - Positive Results
Eli Lilly and Company announced positive topline results from ACHIEVE-3, an open-label randomized P…
Full Summary
|
REGN Regeneron Pharmaceuticals |
$583.69
+1.5% |
+1.7%
|
Semaglutide (GLP-1 receptor agonist)
induced Weight Loss by Preserving Lean Mass
|
Phase 2
|
9/17/2025 - Analysis
Regeneron Pharmaceuticals, Inc announced updated analyses from the ongoing Phase 2 COURAGE trial in…
Full Summary
|
ROIV Roivant Sciences |
$15.52
+9.5% |
+31.4%
 |
Brepocitinib
Systemic Lupus Erythematosus
|
Phase 3
|
9/17/2025 - Positive Results
Roivant and Priovant Therapeutics today announced positive results from the Phase 3 VALOR study eval…
Full Summary
|
LXRX Lexicon Pharmaceuticals |
$1.08
-2.3% |
-11.2%
 |
pilavapadin
For the treatment of diabetic peripheral neuropathic pain (DPNP)
|
Phase 2b
|
9/17/2025 - Data Presentation
Lexicon Pharmaceuticals, Inc announced the presentation of clinical data from the company's Phase 2…
Full Summary
|
IPHA Innate Pharma |
$2.03
-2.6% |
-9.2%
 |
Lacutamab
Treatment of patients with relapsed or refractory Sézary syndrome
|
|
9/17/2025 - Provided Update
Innate Pharma SA provided Business Update
Full Summary
|
ATXS Astria Therapeutics |
$7.56
+4.0% |
+11.5%
 |
STAR-0310
Treatment of Atopic Dermatitis
|
Phase 1a
|
9/17/2025 - Positive Results
Astria Therapeutics, Inc announced positive initial results from the Phase 1a trial of STAR-0310, a…
Full Summary
|
ORKA Oruka Therapeutics |
$15.87
+6.5% |
+4.0%
 |
ORKA-001
Inhibitor IL-23p19
|
Phase 1
|
9/17/2025 - Interim Data
Oruka Therapeutics announced interim data from its Phase 1 trial of ORKA-001, the Company's long-act…
Full Summary
|
ARQT Arcutis Biotherapeutics |
$17.37
+2.3% |
+3.7%
 |
ZORYVE™ (roflumilast)
Inhibitor of phosphodiesterase-4 (PDE4)
|
|
9/17/2025 - New Data
Arcutis Biotherapeutics, Inc. announced that new data on ZORYVE (roflumilast) efficacy across three …
Full Summary
|
INCY Incyte |
$85.62
+2.0% |
+0.8%
 |
povorcitinib
AK1 inhibitor
|
Phase 3
|
9/17/2025 - Interim Data
Incyte announced new 24-week interim data evaluating the safety and efficacy of povorcitinib (INCB54…
Full Summary
|
KYMR Kymera Therapeutics |
$49.33
+1.1% |
+13.1%
 |
KT-621
A potential oral treatment for asthma and other TH2 respiratory diseases.
|
Phase 1
|
9/17/2025 - Positive Results
Kymera Therapeutics announced that the positive results from the Phase 1 healthy volunteer clinical …
Full Summary
|
PTGX Protagonist Therapeutics |
$60.01
+2.4% |
+6.8%
 |
PN-881
oral peptide antagonist blocking the three dimeric forms of IL-17
|
Phase 3
|
9/17/2025 - New Data
Protagonist Therapeutics, Inc. announced new data from the Phase 3 ICONIC-ADVANCE 1 and 2 studies w…
Full Summary
|
ALRN Aileron Therapeutics |
|
|
LTI-03
In Idiopathic Pulmonary Fibrosis
|
|
9/17/2025 - Data Publication
Rein Therapeutics announced the publication of novel data on its lead drug candidate, LTI-03, in iS…
Full Summary
|
CDTX Cidara Therapeutics |
$65.37
+1.0% |
+3.4%
 |
CD388
Universal Prevention and Treatment of Influenza
|
Phase 2b
|
9/17/2025 - Presentation
Cidara Therapeutics, Inc. announced two presentations during the International Society for Respirato…
Full Summary
|
CLDX Celldex Therapeutics |
$24.87
+1.2% |
+1.6%
 |
Barzolvolimab
For Prurigo Nodularis
|
Phase 2
|
9/17/2025 - New Data
Celldex announced today new data demonstrating rapid and strong efficacy regardless of baseline immu…
Full Summary
|
CADL Candel Therapeutics |
$4.92
+1.5% |
-17.4%
 |
CAN-2409
Prostate cancer
|
|
9/17/2025 - Abstract
Candel Therapeutics, Inc. announced that an abstract was accepted for an oral presentation at the 2…
Full Summary
|
BMY Bristol Myers Squibb |
$46.18
-0.3% |
-4.2%
 |
Deucravacitinib
Moderate to severe plaque psoriasis
|
Phase 3
|
9/17/2025 - Data
J&J Announces Data From Phase 3 ICONIC-ADVANCE 1 And 2 Studies Showing Icotrokinra Demonstrated Supe…
Full Summary
|
BWAY Brainsway |
$16.03
-5.1% |
+7.9%
 |
Deep TMS
Decreasing Anxiety Symptoms in Depressed Patients
|
|
9/16/2025 - FDA GRANT
BrainsWay Ltd. announced that the U.S. Food and Drug Administration (FDA) has granted an expansion o…
Full Summary
|
MIRA MIRA Pharmaceuticals |
$1.30
-1.1% |
-12.5%
 |
Ketamir-2
To treat depression and treatment-resistant depression (TRD).
|
|
9/16/2025 - Positive Results
MIRA Pharmaceuticals, Inc announced positive results demonstrating that its oral drug candidate Ket…
Full Summary
|
CYTH Cyclo Therapeutics |
$0.72
|
|
Trappsol® Cyclo™
For the treatment of Niemann-Pick Disease Type C1 (NPC1)
|
Phase 3
|
9/16/2025 - Data
Rafael Holdings, Inc. announced today that data from Cyclo Therapeutics' Phase 3 TransportNPC™ open…
Full Summary
|
ARQT Arcutis Biotherapeutics |
$17.37
+2.3% |
+3.7%
|
ZORYVE™ (roflumilast)
Inhibitor of phosphodiesterase-4 (PDE4)
|
|
9/16/2025 - Presentation
Arcutis Biotherapeutics, Inc announced that ZORYVE was presented with a 2025 Best of Beauty Breakt…
Full Summary
|
MENS Jyong Biotech |
$54.19
-0.4% |
+30.6%
 |
MCS‑8
Prostate Cancer Prevention
|
Phase 2
|
9/16/2025 - Enrollment Update
Jyong Biotech Ltd. announced that it has completed patient enrollment in its Phase II clinical trial…
Full Summary
|
VRNA Verona Pharma PLC American Depositary Share |
$106.28
+0.0% |
+0.5%
 |
Ensifentrine
Chronic obstructive pulmonary disease (COPD)
|
|
9/16/2025 - Poster Presentation
Verona Pharma plc announces two posters on additional analyses from its Phase 3 ENHANCE studies with…
Full Summary
|
MRNA Moderna |
$25.12
+1.1% |
-10.6%
 |
SPIKEVAX (COVID-19 Vaccine, mRNA)
COVID-19 in individuals 18 years of age and older
|
|
9/16/2025 - Positive Data
Moderna, Inc. announced positive preliminary immunogenicity data for the 2025-2026 formula of Spikev…
Full Summary
|
ONCY Oncolytics Biotech |
$1.33
+4.3% |
+31.2%
 |
Pelareorep
In Breast Cancer
|
|
9/16/2025 - Enrollment Update
ncolytics Biotech® Inc. nnounced updates on enrollment progress, U.S. site expansion, and expected d…
Full Summary
|
BMEA Biomea Fusion |
$2.00
-1.2% |
+14.7%
 |
icovamenib
For 2 diabetes
|
|
9/16/2025 - Presentation
Biomea Fusion, Inc. announced the presentation of preclinical data from its investigational menin in…
Full Summary
|
LTRN Lantern Pharma |
$4.01
-2.3% |
-9.8%
 |
LP-184
Prostate cancer
|
Phase 1a
|
9/16/2025 - Provided Update
Lantern Pharma Inc. announced the successful completion of its Phase 1a clinical trial (NCT05933265…
Full Summary
|
CTSO Cytosorbents |
$0.91
+0.4% |
-17.0%
 |
DrugSorb-ATR
Antithrombotic Removal System
|
|
9/16/2025 - Regulatory Update
CytoSorbents Corporation today provided a regulatory update on DrugSorb™-ATR.
Full Summary
|
CRBP Corbus Pharmaceuticals |
$11.60
+12.9% |
+25.4%
 |
CRB-701
Targets the expression of Nectin-4 on cancer cells
|
Fast Track
|
9/16/2025 - Designation Grant
Corbus Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted …
Full Summary
|
VRDN Viridian Therapeutics |
$18.91
+1.3% |
+4.4%
 |
VRDN-003
for patients with moderate-to-severe TED.
|
Phase 3
|
9/15/2025 - Enrollment Update
Viridian Therapeutics, Inc announced that enrollment is complete in REVEAL-1 and REVEAL-2, phase 3 …
Full Summary
|
BIOA BioAge Labs |
$5.03
+2.7% |
+11.3%
 |
BGE-102
For the treatment of obesity.
|
Phase 1
|
9/15/2025 - Primary Endpoint
Shanghai Stock Exchange listed company HitGen Inc congratulates its partner BioAge Labs, Inc on t…
Full Summary
|
KRYS Krystal Biotech |
$155.29
+0.6% |
+6.1%
 |
VYJUVEK
Designed to treat DEB at the molecular level by providing the patient's skin cells the template to make normal COL7 protein,
|
|
9/15/2025 - FDA approved
Krystal Biotech, Inc announced today that the United States Food and Drug Administration (FDA) appr…
Full Summary
|
MRK Merck & Co., Inc. |
$81.08
0.0% |
-3.7%
 |
R-DXd
for Patients with CDH6
|
Breakthrough Therapy
|
9/15/2025 - Designation Grant
Merck announced that Raludotatug deruxtecan (R-DXd) has been granted Breakthrough Therapy Designati…
Full Summary
|
KOD Kodiak Sciences |
$9.36
+0.3% |
-16.8%
 |
KSI-101
in patients with MESI
|
|
9/15/2025 - New Data
Kodiak Sciences Inc. announced today new data from the APEX study of KSI-101 presented at the Reti…
Full Summary
|
ENTX Entera Bio |
$1.80
-1.4% |
-10.3%
 |
OPK-8801003
For Short Bowel Syndrome Patients
|
|
9/15/2025 - Presentation
Entera Bio Ltd. announced the presentation of a poster titled "A First-in-Class Oral GLP-2 Analog fo…
Full Summary
|
LIFE aTyr Pharma |
|
|
Efzofitimod
Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
|
Phase 3
|
9/15/2025 - Top-line results
aTyr Pharma, Inc. announced topline results from the Phase 3 EFZO-FIT™ study of efzofitimod in 268 p…
Full Summary
|
NVCR NovoCure |
$12.72
+0.3% |
+5.2%
 |
Optune Lua
For the Treatment of Metastatic Non-Small Cell Lung Cancer
|
MHLW Approval
|
9/15/2025 - Approved
Novocure announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) approved Optune…
Full Summary
|
FBRX Forte Biosciences |
$11.92
-3.3% |
+0.1%
 |
FB102
In celiac disease
|
|
9/15/2025 - Additional data
Forte Biosciences, Inc announced additional details from the oral presentation "FB102 prevents histo…
Full Summary
|
FBRX Forte Biosciences |
$11.92
-3.3% |
+0.1%
|
FB102
In celiac disease
|
|
9/15/2025 - Additional data
Forte Biosciences, Inc announced additional details from the oral presentation "FB102 prevents his…
Full Summary
|
ATHE Alterity Therapeutics |
$4.40
-1.1% |
-15.7%
 |
ATH434-201
Investigation of ATH434 in patients with early-stage multiple system atrophy (MSA), a rare neurodegenerative disease with no approved treatments to slow or stop its progression.
|
Phase 2
|
9/15/2025 - Data
Alterity Therapeutics announced that data from the ATH434-201 randomized, double-blind Phase 2 cli…
Full Summary
|
KLRS Kalaris Therapeutics |
$4.47
-10.8% |
+78.8%
 |
TH103
in Neovascular Age-Related Macular Degeneration
|
Phase 1b/2
|
9/15/2025 - Enrollment Update
Kalaris Therapeutics, Inc. announced that it is now enrolling a Phase 1b/2 multiple ascending dose (…
Full Summary
|
BLTE Belite Bio |
$72.57
+8.5% |
+11.7%
 |
Tinlarebant
In Stargardt Disease
|
Phase 3
|
9/12/2025 - Provided Update
Belite Bio Inc announced the completion of the last subject visit in the Phase 3 DRAGON clinical tri…
Full Summary
|
DTIL Precision BioSciences |
$4.63
-0.9% |
-6.5%
 |
ARCUS
Eliminate DNA of living cells and organisms.
|
Phase 1
|
9/12/2025 - Clinical Data
Precision BioSciences, Inc announced that the Company presented clinical data from the Phase 1 ELIM…
Full Summary
|
MAZE Maze Therapeutics |
$23.83
+1.6% |
+78.5%
 |
MZE782
first-in-class therapy for patients with CKD.
|
Phase 1
|
9/11/2025 - Positive Results
Maze Therapeutics, Inc. announced positive clinical results from the Phase 1 healthy volunteer stud…
Full Summary
|
LQDA Liquidia Technologies |
$25.63
-1.6% |
-7.6%
 |
LIQ861 (Treprostinil)
Pulmonary arterial hypertension (PAH)
|
|
9/11/2025 - Poster Presentation
Liquidia Corporation announced today that the company will present four posters at the Pulmonary Hyp…
Full Summary
|
FBLG FibroBiologics |
$0.53
-0.8% |
-14.9%
 |
Human dermal fibroblast
in Chronic-Relapse Psoriasis Treatment
|
|
9/11/2025 - Positive Data
FibroBiologics, Inc. announced positive IND-enabling updates from its psoriasis research program de…
Full Summary
|
MRK Merck & Co., Inc. |
$81.08
0.0% |
-3.7%
|
CAPVAXIVE
For the prevention of invasive disease caused by Streptococcus pneumoniae serotypes
|
Phase 3
|
9/11/2025 - Positive Results
Merck announced positive results from the Phase 3 STRIDE-13 trial evaluating CAPVAXIVE® (Pneumococca…
Full Summary
|
LXRX Lexicon Pharmaceuticals |
$1.08
-2.3% |
-11.2%
|
pilavapadin
For the treatment of diabetic peripheral neuropathic pain (DPNP)
|
|
9/11/2025 - Presentation
Lexicon Pharmaceuticals, Inc. announced the presentation of clinical data for its investigational, …
Full Summary
|
ENLV Enlivex Therapeutics |
$1.07
-1.4% |
-14.8%
 |
Allocetra
Sepsis
|
|
9/11/2025 - Provided Update
Enlivex Therapeutics Ltd. today issued the following update to shareholders from Chief Executive Off…
Full Summary
|
APGE Apogee Therapeutics |
$38.46
+4.4% |
+4.2%
 |
APG777
For the Treatment for Atopic Dermatitis and Other Inflammatory Diseases
|
Phase 2
|
9/11/2025 - Data
Apogee Therapeutics, Inc. announced data from the Phase 2 APEX trial of APG777 for moderate-to-seve…
Full Summary
|
IINN Inspira Technologies OXY B.H.N. |
$1.16
+1.0% |
-7.1%
 |
HYLA™
Blood Sensor
|
|
9/11/2025 - Positive Results
Inspira™ Technologies announced pivotal results for its HYLA blood sensor, achieving 97.35% accurac…
Full Summary
|
PRTC PureTech Health |
$14.92
+1.5% |
-24.8%
 |
SPT-320
to treat generalized anxiety disorder
|
Phase 1
|
9/11/2025 - Dose Update
PureTech Health plc announced that the first participant has been dosed in the Phase 1 study of Gl…
Full Summary
|
PTGX Protagonist Therapeutics |
$60.01
+2.4% |
+6.8%
|
IL-23
in Plaque Psoriasis
|
EMA
|
9/11/2025 - Application Submitted
Protagonist Therapeutics, Inc. announced the submission of an application to the European Medicines…
Full Summary
|
RNA Avidity Biosciences |
$40.81
-1.5% |
-8.3%
 |
del-zota
for people living with Duchenne Muscular Dystrophy amenable to exon 44 skipping (DMD44).
|
|
9/10/2025 - Positive Data
Avidity Biosciences, Inc. announced positive new data from participants treated continuously with de…
Full Summary
|
KPTI Karyopharm Therapeutics |
$6.18
-1.4% |
+10.5%
 |
Selinexor
Myelofibrosis
|
Phase 3
|
9/10/2025 - Enrollment Update
Karyopharm Therapeutics Inc. announced that it has completed enrollment in the Phase 3 SENTRY trial…
Full Summary
|
IMRX Immuneering |
$8.13
-2.2% |
+132.3%
 |
Atebimetinib + mGnP
in First-Line Pancreatic Cancer Patients
|
Target date: September 25, 2025
|
9/10/2025 - Survival data
Immuneering plans to announce updated overall survival data in first-line pancreatic cancer patients…
Full Summary
|
GLSI Greenwich LifeSciences |
$11.25
-0.2% |
-6.4%
 |
GLSI-100
Breast cancer recurrences
|
Fast Track
|
9/10/2025 - Designation Grant
Greenwich LifeSciences, Inc announced that FDA has granted Fast Track designation for GLSI-100 in t…
Full Summary
|
TMCI Treace Medical Concepts |
$7.16
+1.3% |
+1.7%
 |
ALIGN3D
Surgical treatment of Hallux Valgus
|
|
9/10/2025 - Highlights
Treace Medical Concepts, Inc announced it will highlight new product innovations and present new in…
Full Summary
|
BTAI BioXcel Therapeutics |
$2.93
-2.0% |
-48.3%
 |
BXCL501 (SERENITY)
Schizophrenia and bipolar disorders
|
Phase 3
|
9/10/2025 - Efficacy Data
BioXcel Therapeutics, announced positive topline exploratory efficacy data from the SERENITY At-Home…
Full Summary
|
RVMD Revolution Medicines |
$44.59
-0.3% |
+22.3%
 |
daraxonrasib
For previously treated metastatic PDAC in patients with KRAS G12 mutations.
|
|
9/10/2025 - Provided Update
Revolution Medicines, Inc announced key clinical updates from its daraxonrasib Phase 1 clinical tri…
Full Summary
|
RNA Avidity Biosciences |
$40.81
-1.5% |
-8.3%
|
EXPLORE44
in People Living with DMD44
|
|
9/10/2025 - Positive Data
Avidity Biosciences, Inc. announced positive new data from participants treated continuously with d…
Full Summary
|
CORT Corcept Therapeutics |
$74.69
+4.7% |
+4.1%
 |
Relacorilant
Recurrent Platinum-Resistant Ovarian Cancer
|
NDA
|
9/10/2025 - FDA Accepted
Corcept Therapeutics Incorporated announced that the U.S. Food and Drug Administration (FDA) has a…
Full Summary
|
ARWR Arrowhead Pharmaceuticals |
$30.05
+2.2% |
+50.9%
 |
ARO-MAPT
Treatment of Alzheimer's Disease and Other Tauopathies
|
Phase 1/2a
|
9/10/2025 - Provided Update
Arrowhead Pharmaceuticals, Inc announced that it has filed a request for regulatory clearance to in…
Full Summary
|
HOTH Hoth Therapeutics |
$1.77
-3.4% |
+37.0%
 |
HT-001
Cancer patients suffering from cutaneous toxicities (skin, nails, scalp) due to EGFR
|
EMA
|
9/10/2025 - Clinical trial application
Hoth Therapeutics, Inc announced it has submitted its Clinical Trial Application (CTA) to the Europ…
Full Summary
|
PMVP PMV Pharmaceuticals |
$1.33
+10.4% |
-14.8%
 |
rezatapopt
in patients with advanced solid tumors
|
Phase 2
|
9/10/2025 - Interim Data
PMV Pharmaceuticals, announced interim data from the Phase 2 pivotal portion of the PYNNACLE clinic…
Full Summary
|
TGTX TG Therapeutics |
$32.34
+1.1% |
+16.6%
 |
BRIUMVI® (ublituximab-xiiy)
For treat relapsing forms of multiple sclerosis (MS).
|
|
9/10/2025 - Presentation
TG Therapeutics, Inc. announced the upcoming schedule of presentations highlighting BRIUMVI® (ublitu…
Full Summary
|
TIL Instil Bio |
$21.59
-6.3% |
-25.2%
 |
AXN-2510
In Relapsed/Refractory Solid Tumors
|
Phase 1
|
9/10/2025 - Efficacy Data
Instil Bio, Inc. announced that ImmuneOnco Biopharmaceuticals (Shanghai) Inc. presented preliminary…
Full Summary
|
ASRT Assertio |
$0.94
+12.4% |
+16.5%
 |
SYMPAZAN
treatment of seizures associated with Lennox-Gastaut syndrome in patients two years of age or older
|
|
9/10/2025 - Data Presentation
Assertio Holdings, Inc. announced that the company will present new data for SYMPAZAN (clobazam) Ora…
Full Summary
|
TVTX Travere Therapeutics |
$23.44
+2.9% |
+24.9%
 |
FILSPARI
Endothelin and angiotensin II receptor antagonist indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a UPCR ≥1.5 g/g.
|
supplemental New Drug Application (sNDA)
|
9/10/2025 - review
Travere Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has informed t…
Full Summary
|
INCY Incyte |
$85.62
+2.0% |
+0.8%
|
povorcitinib
AK1 inhibitor
|
|
9/10/2025 - Data Presentation
Incyte announced that it will present new data from its dermatology portfolio at the European Associ…
Full Summary
|
WALD Waldencast |
$1.96
+10.1% |
+8.8%
 |
MagIQ™
|
|
9/10/2025 - FDA approved
Waldencast plc announced that the U.S. Food and Drug Administration ("FDA") has approved Obagi® sayp…
Full Summary
|
SGHT Sight Sciences |
$3.49
0.0% |
-16.7%
|
OMNI Device
Canal Viscodilation in Combination with Cataract Surgery in Adults with Primary Open-Angle Glaucoma (POAG)
|
|
9/9/2025 - Provided Update
Sight Sciences, Inc. announced that UnitedHealthcare (UHC) has updated its Glaucoma Surgical Treatm…
Full Summary
|
CGEM Cullinan Therapeutics |
$6.06
-3.7% |
-23.8%
 |
zipalertinib
For patients with heavily pre-treated EGFR ex20ins mutation NSCLC
|
|
9/9/2025 - New Data
Taiho Oncology, Inc., and Cullinan Therapeutics, Inc announced new data from the REZILIENT1 and RE…
Full Summary
|
XLO Xilio Therapeutics |
$0.76
-1.3% |
+6.9%
 |
XTX301
Solid tumors
|
Phase 2
|
9/9/2025 - Dose Update
Xilio Therapeutics, Inc. announced the initiation of patient dosing in Phase 2 of an ongoing Phase…
Full Summary
|
IONS Ionis Pharmaceuticals |
$61.64
+0.5% |
+41.9%
 |
ION582
Angelman syndrome
|
Breakthrough Therapy
|
9/9/2025 - Designation Grant
Ionis Pharmaceuticals, Inc announced that the U.S. Food and Drug Administration (FDA) has granted B…
Full Summary
|
ACRS Aclaris Therapeutics |
$1.85
+0.3% |
-0.3%
 |
ATI-2138
For the Treatment of Moderate to Severe Atopic Dermatitis
|
Phase 2a
|
9/9/2025 - Abstract
Aclaris Therapeutics, Inc. announced that a late-breaking abstract on its open-label Phase 2a trial…
Full Summary
|
EBS Emergent Biosolutions |
$7.84
+0.1% |
-13.5%
 |
ACAM2000®
For Mpox Indication
|
|
9/9/2025 - Provided Update
Emergent BioSolutions Inc. announced that a contract modification has been executed in the amount …
Full Summary
|
CAPR Capricor Therapeutics |
$6.15
-1.2% |
-20.2%
 |
deramiocel
For the treatment of Duchenne muscular dystrophy (DMD)
|
BLA
|
9/9/2025 - Provided Update
Capricor Therapeutics today issued a statement regarding the U.S. Food and Drug Administration's (F…
Full Summary
|
MBRX Moleculin Biotech |
$0.39
+4.9% |
-35.6%
 |
Annamycin
Soft tissue sarcoma (STS) lung metastases
|
Phase 2b/3
|
9/9/2025 - Provided Update
Moleculin Biotech, Inc announced updates to its active site status and recruitment for its pivotal …
Full Summary
|
AGEN Agenus |
$4.54
+1.6% |
+0.3%
 |
BOT/BAL
In Metastatic MSS Colorectal Cancer
|
|
9/9/2025 - Provided Update
Agenus Inc announced its investigational combination botensilimab plus balstilimab (BOT/BAL) is now …
Full Summary
|
NKTR Nektar Therapeutics |
$50.77
+1.8% |
+85.1%
 |
Rezpegaldesleukin
For the treatment of atopic dermatitis.
|
Phase 2b
|
9/9/2025 - Presentation
Nektar Therapeutics announced today that it will present results from the ongoing REZOLVE-AD Phase 2…
Full Summary
|
CMRX Chimerix |
$8.54
|
|
dordaviprone
treatment for recurrent H3 K27M-mutant diffuse glioma
|
|
9/9/2025 - Provided Update
Jazz Pharmaceuticals plc announced that Modeyso™ (dordaviprone) is recommended by the National Comp…
Full Summary
|
MBOT Microbot Medical |
$3.32
-0.5% |
+7.9%
 |
LIBERTY® Robotic Surgical System
Device
|
|
9/9/2025 - Provided Update
Microbot Medical Inc. announced that Harel Gadot, CEO, President & Chairman, will highlight the rece…
Full Summary
|
JAZZ Jazz Pharmaceuticals |
$129.55
+2.4% |
+10.1%
 |
dordaviprone
treatment for recurrent H3 K27M-mutant diffuse glioma
|
|
9/9/2025 - Provided Update
Jazz Pharmaceuticals plc announced that Modeyso™ (dordaviprone) is recommended by the National Comp…
Full Summary
|
CRSP CRISPR Therapeutics |
$59.52
-2.7% |
+3.3%
 |
CTX310
Treatments for Cardiovascular Diseases
|
|
9/9/2025 - Late Breaking Presentation
CRISPR Therapeutics announced that a late-breaking oral presentation highlighting the Company's Pha…
Full Summary
|
ALKS Alkermes |
$27.93
+2.0% |
-0.6%
 |
ALKS 2680
For the treatment of narcolepsy
|
Phase 2
|
9/8/2025 - Positive Results
Alkermes plc announced detailed positive results from the Vibrance-1 phase 2 study evaluating alixor…
Full Summary
|
TAK Takeda Pharmaceutical |
$15.14
+0.1% |
-0.3%
 |
TAK-861
In patients with moderate to severe obstructive sleep apnea undergoing general anesthesia.
|
Phase 3
|
9/8/2025 - Data Presentation
Takeda will present data from two global Phase 3 double-blind, placebo-controlled studies of ovepore…
Full Summary
|
LLY Eli Lilly and Company |
$763.36
-0.2% |
+9.2%
|
Pirtobrutinib
A non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, in adult
|
Phase 3
|
9/8/2025 - Top-line results
Eli Lilly and Company announced positive topline results from the Phase 3 BRUIN CLL-313 clinical tr…
Full Summary
|
PFE Pfizer |
$24.08
+0.8% |
-3.9%
 |
COMIRNATY® LP.8.1
For active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older.
|
Phase 3
|
9/8/2025 - Top-line results
Pfizer Inc. and BioNTech SE announced positive topline results from an ongoing Phase 3 clinical tri…
Full Summary
|
TGTX TG Therapeutics |
$32.34
+1.1% |
+16.6%
|
BRIUMVI® (ublituximab-xiiy)
For treat relapsing forms of multiple sclerosis (MS).
|
Phase 3
|
9/8/2025 - Enrollment Update
TG Therapeutics, Inc. announced today that enrollment has commenced in a Phase 3 trial evaluating su…
Full Summary
|
REGN Regeneron Pharmaceuticals |
$583.69
+1.5% |
+1.7%
|
REGN1908
Antibody-Blockers of Cat and Birch Allergies
|
Phase 3
|
9/8/2025 - Results
Regeneron Pharmaceuticals, Inc announced results evaluating its first-in-class investigational all…
Full Summary
|
TNXP Tonix Pharmaceuticals |
$28.01
+3.3% |
-30.1%
|
Tonmya
For the management of fibromyalgia.
|
|
9/8/2025 - Poster Presentation
Tonix Pharmaceuticals presented four posters at the PAINWEEK conference 2025, held September 2-5, 20…
Full Summary
|
PLSE Pulse Biosciences |
$16.29
-2.1% |
+3.9%
 |
nsPFA
Treatment of Atrial Fibrillation
|
|
9/8/2025 - FDA approved
Pulse Biosciences, Inc announced that the U.S. Food and Drug Administration (FDA) has granted approv…
Full Summary
|
IDYA IDEAYA Biosciences |
$24.72
0.0% |
-0.1%
 |
Darovasertib
Non-metastatic uveal melanoma (UM)
|
|
9/8/2025 - Data Presentation
IDEAYA Biosciences, Inc. will present positive interim data at their 10-Year Anniversary R&D Day fro…
Full Summary
|
KROS Keros Therapeutics |
$15.81
+0.0% |
+8.8%
 |
KER-065
To treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins
|
Phase 1
|
9/8/2025 - Additional data
Keros Therapeutics, announced that it presented additional clinical data from its Phase 1 clinical t…
Full Summary
|
MDCX Medicus Pharma |
$2.40
-8.0% |
+20.0%
 |
SKNJCT-004
To Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
|
Phase 2
|
9/8/2025 - Clinical Study
Medicus Pharma Ltd is pleased to announce that the SKNJCT-004 phase 2 clinical study, to non-invasi…
Full Summary
|
